MMRV vaccine
| Combination of | |
|---|---|
| Measles vaccine | Vaccine |
| Mumps vaccine | Vaccine |
| Rubella vaccine | Vaccine |
| Varicella vaccine | Vaccine |
| Clinical data | |
| Trade names | Proquad, Priorix Tetra |
| Other names | Measles, Mumps, Rubella, and Varicella Virus Vaccine Live |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous, intramuscular |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| (what is this?) (verify) | |
The MMRV vaccine is a combination vaccine against measles, mumps, rubella (German measles), and varicella (chickenpox), abbreviated as MMRV. The MMRV vaccine has similar immunogenicity and overall safety profiles to the MMR vaccine administered with or without the varicella vaccine. The MMRV vaccine is typically given to children between one and two years of age.
Several companies supply MMRV vaccines. Proquad is marketed by Merck and was approved in 2005, for use in the United States by the Food and Drug Administration (FDA) for children ages twelve months through twelve years. Stand-alone virus measles, mumps, rubella, and varicella vaccines had been previously licensed in 1963, 1967, 1969, and 1995, respectively. An MMRV vaccine called Priorix Tetra by GlaxoSmithKline has been approved in Germany and Australia.